Prof Matti Aapro speaks to ecancer at BGICC 2019 in Cairo about a debate covering the testing of Next Generation Sequencing in metastatic breast cancer patients.

He argues against NGS, saying that there is no evidence saying that it has to be done.

Prof Aapro also believes there is not much to learn from NGS compared to standard pathology, and even a molecular signal from NGS is not necessarily enough evidence for a articular drug to be used.

See the opposing view from Prof Edith Perez here.